BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Archives for Cade Hildreth (CEO) » Page 265

Induced Pluripotent Stem Cell News Round-Up| February 15-22, 2015

February 20, 2015 By Cade Hildreth (CEO) Leave a Comment

iPSC News Round-Up February 2014

The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area.  Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: cell therapy, current events, iPSC, market update, stem cells

Induced Pluripotent Stem Cell (iSPC) News Round-Up| January 2015

February 20, 2015 By Cade Hildreth (CEO) Leave a Comment

iPSC News Round-Up February 2014

The induced pluripotent stem cell (iPSC) industry is a rapidly evolving area.  Since the discovery of iPSCs in 2006, there have been a number of important market events that have occurred, including the first ever clinical trial in humans that was initiated in August 2013 to investigate iPSC-derived cell sheets for restoring vision, as well as large funding awards, major initial public offerings (IPOs), critical patent challenges, and more. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: cell therapy, current events, iPSC

Cord Blood Scientific Publications May Predict What Will Happen in 2015 and Beyond

February 20, 2015 By Cade Hildreth (CEO) Leave a Comment

Cord Blood Scientific Publications - Past Analysis and Future Projections

Trend rate data is valuable for understanding current industry conditions, as well as for predicting future behavior within the cord blood industry.

In upcoming posts, we will be presenting a range of valuable trend rate data, pulled from diverse sources, including grant funding databases, patent databases, clinical trial databases, and more.

In this post, we will begin with an analysis of scientific publication rate data for cord blood industry, because it is an important way to gauge innovation and progress within the marketplace.

Scientific Publication Rate Analysis

PubMed is a service of the U.S. National Library of Medicine and the National Institutes of Health (NIH) that contains citations from MEDLINE and a diverse collection of other life science journals. The data below was generated using the PubMed database, because it is the largest, most comprehensive, and most up-to-date global meta-database available for scientific publications.[1]

It is also the most versatile tool for screening by multiple criteria. [Read more…]

Filed Under: Cord Blood, HSCs Tagged With: cord blood, cord tissue, hematopoietic stem cells, market research, market trends

Advantages of Umbilical Cord Blood for Use in HSCT

February 20, 2015 By Cade Hildreth (CEO) Leave a Comment

Technical Advantages of Cord Blood

The stem cells found in cord blood are largely hematopoietic stem cells, which can help in the replenishment of a depleted blood supply by providing new, healthy cells. In the case of certain diseases, such as leukemia, anemia, lymphoma, and others where the blood cells and tissues are severely affected, this replenishment is essential.

There are several important properties of cord blood, including that the number of hematopoietic stem cells in cord blood equals, or exceeds, the frequency of hematopoietic stem cells in bone marrow. In addition, cord blood hematopoietic stem cells can produce large colonies in vitro, have different growth factor requirements, and can be expanded in long-term culture.[1]

Also, cord blood stem cells are characterized as multipotent, because they are capable of differentiating into numerous stem cell types, including neurons, hepatic cells, and circulating cell types.[2]
[Read more…]

Filed Under: Cord Blood, HSCs Tagged With: cord blood, cord blood transplant, hematopoietic stem cells, technical advantages

“Cord Blood” Reaches Nearly $40 Per Click in the U.S. and More Than $20 Per Click Worldwide

February 18, 2015 By Cade Hildreth (CEO) 1 Comment

Cord Blood Reaches One of the 20 Most Expensive Search Terms on Google

Because Google controls over 70% of online searches, it is an incredible resource for analyzing online search behavior. Recently, the search term “Cord Blood” became one of the 20 most expensive keywords on Google Adwords,[1] an incredible finding given the variety and total volume of searches that occur through Google.

Individuals or companies who buy the exact search phrase “Cord Blood” through Google AdWords now pay $38.38[2] to win search traffic for this phrase within the United States. [Read more…]

Filed Under: Cord Blood, HSCs, MSCs Tagged With: cord blood, cord blood market, google adwords, hematopoietic stem cells, industry trends, market research, mesenchymal stem cells

  • « Previous Page
  • 1
  • …
  • 263
  • 264
  • 265
  • 266
  • 267
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.